Biofrontera Inc.
BFRI
$0.82
$0.011.12%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.17M | 39.19M | 38.00M | 37.32M | 35.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.17M | 39.19M | 38.00M | 37.32M | 35.36M |
| Cost of Revenue | 13.23M | 16.06M | 17.76M | 18.61M | 18.70M |
| Gross Profit | 23.94M | 23.13M | 20.24M | 18.72M | 16.66M |
| SG&A Expenses | 37.84M | 35.90M | 33.25M | 33.84M | 34.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.78M | 55.49M | 54.29M | 54.53M | 54.72M |
| Operating Income | -17.62M | -16.30M | -16.29M | -17.21M | -19.36M |
| Income Before Tax | -17.55M | -16.57M | -11.51M | -17.74M | -12.82M |
| Income Tax Expenses | 23.00K | 20.00K | 19.00K | 21.00K | 18.00K |
| Earnings from Continuing Operations | -17.57 | -16.59 | -11.53 | -17.76 | -12.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.57M | -16.59M | -11.53M | -17.76M | -12.84M |
| EBIT | -17.62M | -16.30M | -16.29M | -17.21M | -19.36M |
| EBITDA | -17.51M | -16.08M | -15.97M | -16.79M | -18.85M |
| EPS Basic | -1.84 | -2.21 | -1.69 | -4.10 | -2.27 |
| Normalized Basic EPS | -1.28 | -1.51 | -1.18 | -2.63 | -3.32 |
| EPS Diluted | -2.03 | -2.39 | -1.88 | -4.28 | -2.27 |
| Normalized Diluted EPS | -1.28 | -1.51 | -1.18 | -2.63 | -3.32 |
| Average Basic Shares Outstanding | 36.57M | 31.57M | 27.31M | 22.06M | 16.63M |
| Average Diluted Shares Outstanding | 36.57M | 31.57M | 27.31M | 22.06M | 16.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |